Raphael Pharmaceutical (RAPH) Cash from Financing Activities (2020 - 2025)

Raphael Pharmaceutical has disclosed Cash from Financing Activities across 6 years of filings, most recently posting -$4000.0 for Q4 2025.

• Cash from Financing Activities for Q4 2025 came in at -$4000.0, down 109.76% year-over-year; the trailing twelve-month figure through Dec 2025 was $236000.0 (down 26.48% YoY), and the FY2025 annual result was $236000.0, down 26.48% from the prior year.
• Cash from Financing Activities came in at -$4000.0 for Q4 2025 at Raphael Pharmaceutical, down from $240000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $820000.0 in Q4 2021 to a low of -$4000.0 in Q4 2025.
• The 5-year median for Cash from Financing Activities is $149000.0 (2023), against an average of $239705.9.
• Across the five-year window, Cash from Financing Activities surged 1390.0% in 2023 and tumbled 109.76% in 2025, its largest moves.
• Raphael Pharmaceutical's Cash from Financing Activities stood at $820000.0 in 2021, then tumbled by 42.44% to $472000.0 in 2022, then plunged by 95.97% to $19000.0 in 2023, then surged by 115.79% to $41000.0 in 2024, then sank by 109.76% to -$4000.0 in 2025.
• The last three Cash from Financing Activities figures came in at -$4000.0 (Q4 2025), $240000.0 (Q1 2025), and $41000.0 (Q4 2024), per Business Quant data.